PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on HALO:
Disclaimer & DisclosureReport an Issue
Merck granted review of Halozyme patent claims by PTAB
Halozyme's Strategic Positioning and Market Potential Drive Buy Rating
Halozyme announces EC approval of Bristol Myers' Opdivo developed with Enhanze
Optimistic Buy Rating for Halozyme Amid Price Control Concerns
Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Merck to Acquire Verona for $10 Billion, Targeting Life Beyond Keytruda
Merck (MRK, Financials) is spending $10 billion to acquire U.K.-based Verona Pharma, the company announced Wednesday; the move is part of Merck's push to diversify its drug portfolio as its blockbuster cancer drug Keytruda approaches major patent cliffs starting in 2028. Warning! GuruFocus has detected 3 Warning Sign with MRK. Verona brings with it Ohtuvayre, an inhaled treatment for chronic obstructive pulmonary disease, often known as smoker's lung. The drug was approved earlier this year and has generated $42.3 million in sales so far in 2024; analysts see long-term potential, estimating peak annual revenue could top $3 billion. Merck will pay $107 per American depository sharerepresenting a 23% premium to Verona's last Nasdaq close. Shares of Verona surged 20% in premarket trading following the announcement; Merck edged slightly higher. This is Merck's largest deal since its $10.8 billion acquisition of Prometheus Biosciences in 2023 and adds to its growing pipeline of late-stage assets. The company has made a string of acquisitions since 2021, including the $11.5 billion Acceleron deal, which brought in Winrevaira treatment for pulmonary arterial hypertension. While analysts generally welcomed the Verona deal, some flagged that Merck still has work to do to assure investors it can offset looming Keytruda losses. This looks like a potential complementary therapy, said Kevin Gade of Bahl & Gaynor. But others, like BMO Capital's Evan Seigerman, noted that one acquisition won't be enough to fully bridge the gap. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Merck (NYSE:MRK) To Present Promising HIV Research Data At IAS 2025 In Kigali
Merck recently announced updates on its HIV research, which are set to be unveiled at the upcoming International AIDS Society Conference. This announcement, coupled with the company's ongoing project developments and regulatory updates, such as the FDA's acceptance of a supplemental Biologics License Application for WINREVAIR, might have bolstered investor sentiment. Over the last quarter, Merck's share price increased by 2.47%. During this period, broader market movements, including trade uncertainties affecting major indices, showed mixed directions, with the overall market staying relatively flat, suggesting Merck's performance aligned with the broader market trends. Every company has risks, and we've spotted 1 weakness for Merck you should know about. These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. The recent updates on Merck's HIV research, paired with developments related to the supplemental Biologics License Application for WINREVAIR, hold potential implications for the company's growth narrative. These advancements might positively influence Merck's revenue by bolstering its product pipeline, which is projected to introduce over 20 new growth drivers with significant commercial potential. As a result, long-term earnings forecasts could see an upward adjustment, aligning with the company's efforts to maintain leadership in key therapeutic areas. Over a five-year period, Merck's total return, encompassing both share price appreciation and dividends, was 28.14%. This is noteworthy given the 12.5% return for the US market over the past year, despite the company's underperformance relative to the broader market and industry decline. Such performance over time suggests resilience and long-term growth potential, despite facing short-term market volatility and challenges from competitors within the pharmaceuticals sector. Regarding the current share price, which sits at US$79.04, Merck's price target of US$105.02 implies a potential share price increase of 24.7%. The market's reaction to the company's recent news could be a contributing factor to bridging this gap, if the projected growth in revenue and earnings materializes effectively. Investors might consider these elements in evaluating Merck's long-term value proposition. According our valuation report, there's an indication that Merck's share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:MRK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
8 hours ago
- Business Wire
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 (MK-8527-011, NCT 07044297) trial will evaluate the safety and efficacy of MK-8527 among people with greater likelihood of HIV-1 exposure in 16 countries and will begin enrolling in August 2025. In collaboration with the Gates Foundation, the EXPrESSIVE-10 (MK-8527-010) trial will evaluate the safety and efficacy of MK-8527 in women and adolescent girls in sub-Saharan Africa and will begin enrolling in the next few months. 'According to UNAIDS, 1.3 million people acquired HIV in 2023, highlighting the continued need for new PrEP options like our investigational once-monthly, oral PrEP candidate MK-8527, especially among women in sub-Saharan Africa and men who have sex with men, who experience disproportionately high rates of HIV,' said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. 'Our collaboration with the Gates Foundation will help us explore the potential of MK-8527 to contribute to global efforts to reduce the number of HIV infections and help support opportunities to accelerate access around the world.' The decision to initiate the Phase 3 clinical trial program was supported by the results of a double-blind, multicenter, Phase 2 trial (MK-8527-007, NCT 06045507) examining the safety and pharmacokinetics of MK-8527. The study enrolled 350 participants, 18–65 years of age, with low likelihood of HIV-1 exposure, who were randomized 2:2:2:1 to receive MK-8527 (3, 6, or 12 mg) or placebo once monthly for six months. In the trial, the rates of adverse events were similar among those in the MK-8527 arms and those in the placebo arm, and no clinically meaningful changes were seen in laboratory tests, including total lymphocyte and CD4 T-cell counts. The pharmacokinetics of MK-8527 and MK-8527-TP, the active form of MK-8527, support the continued development of MK-8527 as an oral, once-monthly option for PrEP. Results from the Phase 2 trial were highlighted in the opening press conference for IAS 2025, the 13th International AIDS Society Conference on HIV Science in Kigali, Rwanda, on Monday, July 14, at 15:30 – 16:30 CAT, titled 'Breakthroughs Amid Crisis: The Future of HIV Innovation.' These research findings will be further detailed in a late-breaker oral session on Wednesday, July 16, at 12:15 – 13:15 CAT. 'Scientific advances against HIV have brought us further than ever imagined and are ushering in a new era in HIV prevention,' said Trevor Mundel, president of global health at the Gates Foundation. 'With only 18% of global PrEP need currently met, there is a clear and urgent need for options like MK-8527 that may offer the ability to prevent infection. These Phase 3 trials are a key step toward translating progress into longer-acting options that could help turn the tide on HIV.' In the EXPrESSIVE-10 trial, the International Clinical Research Center (ICRC) within the University of Washington Department of Global Health, in partnership with the University of Alabama at Birmingham, will receive grant funding from the Gates Foundation to support ICRC's collaboration with 31 clinical research trial sites in Kenya, South Africa, and Uganda; sites will inform and engage communities and recruit, enroll, and follow women who participate in the EXPrESSIVE-10 trial. Merck will be the trial sponsor, gaining regulatory and customs approvals, and providing operational expertise and resources for management of the trials. The Gates Foundation will also provide support for global community advisory groups, which will offer insight into community perspectives on a monthly PrEP pill, participant recruitment materials and strategies, and cultural considerations for these trials. Separately, the Gates Foundation will provide grant funding for EXPrESSIVE-11 to support the establishment of a community advisory group and the development of recruiting and retention materials only. About the EXPrESSIVE MK-8527 Phase 3 Clinical Trial Program The EXPrESSIVE-11 trial (MK-8527-011, NCT 07044297) is a randomized, active-controlled study enrolling 4,390 sexually active people who could benefit from PrEP across trial sites in 16 countries. The primary objective of the study is to evaluate the efficacy, safety, and tolerability of once-monthly oral MK-8527 compared to daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as assessed by the incidence rate per year of adjudicated HIV-1 infections. The trial will begin enrolling in August 2025. The EXPrESSIVE-10 trial (MK-8527-010) is a randomized, active-controlled study enrolling 4,580 sexually active women aged 16 to 30 in Kenya, South Africa, and Uganda. The primary objective of the study is to evaluate the efficacy, safety, and tolerability of once-monthly oral MK-8527 compared to daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as assessed by the incidence rate per year of adjudicated HIV-1 infections. The study will begin enrolling in the next few months. About MK-8527 MK-8527 is being evaluated as a potential once-monthly oral prevention option for HIV-1. MK-8527 inhibits reverse transcriptase through multiple mechanisms of action, including inhibition of translocation and delayed chain termination. For an overview of Merck's complete HIV treatment and prevention clinical development program, please click here. Merck's Commitment to HIV For more than 35 years, Merck has been committed to scientific research and discovery in HIV, leading to scientific breakthroughs that have helped change HIV treatment. Our work has helped pioneer the development of new options across multiple drug classes to help those impacted by HIV. Today, we are developing a series of antiviral options designed to help people manage their HIV and to help prevent HIV, with the goal of reducing the growing burden of HIV worldwide. We want to ensure people are not defined by HIV, and our work focuses on transformational innovations, collaborations with others in the global HIV community, and access initiatives aimed at helping to end the HIV epidemic for everyone. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube, and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
